These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8221671)

  • 1. Sequence-specific interaction of a conformational domain of p53 with DNA.
    Srinivasan R; Roth JA; Maxwell SA
    Cancer Res; 1993 Nov; 53(22):5361-4. PubMed ID: 8221671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
    Srinivasan R; Maxwell SA
    Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of cellular proteins to a conformational domain of tumor suppressor protein p53.
    Maxwell SA; Roth JA
    Oncogene; 1993 Dec; 8(12):3421-6. PubMed ID: 8247546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.
    Stürzbecher HW; Brain R; Addison C; Rudge K; Remm M; Grimaldi M; Keenan E; Jenkins JR
    Oncogene; 1992 Aug; 7(8):1513-23. PubMed ID: 1321401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism.
    Hainaut P; Rolley N; Davies M; Milner J
    Oncogene; 1995 Jan; 10(1):27-32. PubMed ID: 7824276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells.
    Schmieg FI; Simmons DT
    Oncogene; 1993 Aug; 8(8):2043-50. PubMed ID: 8393158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
    Niewolik D; Vojtesek B; Kovarik J
    Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex of simian virus large T antigen and p53 can bind DNA specifically.
    Long SB; Ho HY; Chen CL; Lai MD
    Anticancer Res; 1995; 15(4):1375-80. PubMed ID: 7654024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K; Li B; Bartel P; Fields S
    Oncogene; 1993 Jun; 8(6):1693-6. PubMed ID: 8502489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein.
    Martin DW; Subler MA; Muñoz RM; Brown DR; Deb SP; Deb S
    Biochem Biophys Res Commun; 1993 Aug; 195(1):428-34. PubMed ID: 8395834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
    Hainaut P; Milner J
    Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
    Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
    Tarunina M; Jenkins JR
    Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 DNA binding can be modulated by factors that alter the conformational equilibrium.
    McLure KG; Lee PW
    EMBO J; 1999 Feb; 18(3):763-70. PubMed ID: 9927436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.